WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves ...

WASHINGTON, DC—How patients weigh the opinions of their family and friends when making decisions about PAD varies by sex and ...

WASHINGTON, DC—How patients weigh the opinions of their family and friends when making decisions about PAD varies by sex and ...

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.

Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.

While discussions about the lack of a mortality effect will continue, some say the findings may be enough to change ...

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.

Several experts argue that AI-QCA is not a replacement for OCT, but could be valuable in low-resource settings.

A clinically relevant question without a definitive answer means larger trials are needed to provide clarity, the ...

The result calls into question the prospects of FDA approval for the Acurate neo2 valve, which is already in use globally.